Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid

Frederic Lezot (1) , Julie Chesneau (2) , Benjamin Navet (3) , Bérengère Gobin (4) , Jérôme Amiaud (4) , Yongwon Choi (5) , Hideo Yagita (6) , Beatriz Castaneda (7) , Ariane Berdal (8) , Christopher Mueller , Françoise Rédini (4) , Dominique Heymann (9)

1 Biologie oro-faciale et pathologie
2 Equipe LIGUE Nationale Contre le Cancer 2012
3 GMGM - Génétique moléculaire, génomique, microbiologie
4 PhAN - Physiopathologie des Adaptations Nutritionnelles
5 Department of Pathology and Laboratory Medicine
6 Department of Immunology
7 CRC (UMR_S 872) - Centre de Recherche des Cordeliers
8 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
9 Department of Oncology and Metabolism [Sheffield, UK]

Domaines: Sciences pharmaceutiques

Frederic Lezot, Julie Chesneau, Benjamin Navet, Bérengère Gobin, Jérôme Amiaud, et al.. Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid. BONE, 2015, 73, pp.51-59. ⟨10.1016/j.bone.2014.12.011⟩. ⟨hal-02884710⟩